Home
overview

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018, featuring two half-day post-conference workshop on the 11th July!

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.


*Source: http://bit.ly/2hMJcgU


Join our expert speaker panel at the 13th annual ADMET conference to ensure you do not miss out on the latest developments!

Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.

 



 

The 13th annual ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling softwares to the validation of humanised mice models.

 

Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

ADME/PK Optimisation for Drug Design and Discovery
Physiochemical Assessments
Drug Screening Technology
In Vitro to Human In Vivo Translation
Physiologically Based PK Modeling
DMPK, PBPK, PKPD
Pre-/Clinical Toxicity
Biologics
Accurate First-in-Human Dose Predictions
Transporters, Bioavailability, Formulation
Drug Delivery
Metabolism Studies
Drug-Drug Interactions
In vivo / in vitro / in silico
Hazard and Safety Assessment
Predictive Toxicology
Preclinical Pharmacology Testing
 

DMPK Professionals
Pharmacologists
Computational Scientists
Medicinal Chemists
Statisticians
Principle scientist
Drug Metabolism Experts
ADME Toxicologists
Research fellows
PK/PD modeling
Toxicologist
Anatomists
 

AbbVie; Actelion; Astrazeneca; Bayer; Corning Life Sciences; Daiichi-Sankyo Europe GmbH; Drugs for Neglected Diseases initiative (DNDi); Galapagos; Galapagos NV; Gedeon Richter; Genentech, Inc.; GlaxoSmithKline; GSK; Heptares Therapeutics; Imperial College London; Institute of Cancer Research; Japan Tobacco; Merck KGaA; Merck Serono; NESTLE SKIN HEALTH - GALDERMA; Novartis Pharmaceuticals Corporation; Pfizer; Proximagen; Proximagen Group plc; Roche Pharmaceuticals; Sanofi; Sekisui Xenotech LLC; Solvo Biotechnology; Sygnature Discovery Ltd; Triskelion B.V.; UCB; UCL Institute of Ophthalmology; Vertex Pharmaceuticals;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Novel Technologies and Computational Tools in Discovery Toxicology: Opportunities and Challenges

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

• Driving nonclinical safety-related attrition to sustainable levels
• Technologies to define target-related safety
• Computational prediction of off-target interactions
• Opportunistic use of in vitro models to tackle complex toxicity issues
 

9:50 How advanced are our in vitro discovery toxicology assays for predicting DILI risks

Timothy Schulz-Utermoehl

Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery Ltd
View Bio

• Generating an understanding as to when predictive in vitro screening should be performed in Discovery
• Use of case studies to qualify the predictability of the available in vitro assays
• Defining if potential metabolites should be screened alongside the active drug
 

10:30 Morning Coffee

11:00 Understanding the correlation between drug exposure, efficacy and toxicity in a transporter mediated drug-drug interaction

Kunal Taskar

Kunal Taskar, Senior Investigator & Associate Fellow, GSK

• Pushing towards more accurate and efficient drug testing in vitro, and most importantly leading the way towards a reduction in animal testing
• Examples of novel toxicity test platforms: embryonic stem cells
• Organ-on-a-Chip: CN Bio Innovations Limited’s collaboration with AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens
• Ex Vivo – The best design to establish causality and to detect effects?
 

11:40 Spotlight: First in human dose predictions

Peter Littlewood

Peter Littlewood, Director DMPK, Vertex Pharmaceuticals

12:20 Networking Lunch

13:50 PKPB - strengths and limitations of compartmental modelling

14:30 PKPD - fundamentals of exposure

15:10 Afternoon Tea

15:40 Advances in PBPK modellin software

16:20 Applicatios of PKPD modelling in oncology - an overview

Pau Aceves

Pau Aceves, Associate Director, Certara Strategic Counselling
View Bio

• Binary safety/efficacy endpoints are simplifications and often based on relatively arbitrary thresholds of underlying biological longitudinal process
• Patients’ individual characteristics may have as big impact on e.g. safety response as solely a dose
• Processes underlying dose-limiting toxicities in Oncology are often reversible therefore how do we best manage toxicity?
• PK and PKPD time-course described via a mechanistic model, thus may be used for predictions, where fixed AND random effects are estimated.
 

17:00 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Discovering biopharmaceuticals

9:50 Biotransformation of biotherapeutics - Impact on candidate selection

Filipe Lopes

Filipe Lopes, DMPK Laboratory Head, Roche
View Bio

• Metabolism of Small-Molecule Drugs vs Biotherapeutics
• Impact of Protein Biotherapeutics Biotransformation on BIoanalysis
• Workflows for Studying Protein Biotherapeutics
• The future of the field
 

10:30 Morning Coffee

11:00 Advances in models for the prediction of human drug metabolism

Ian Wilson

Ian Wilson, Chair, Drug Metabolism and Molecular Toxicology, Imperial College
View Bio

• Avoiding problems in drug development requires good methods for the prediction of drug metabolism/toxicology.
• Accurate models that to predict liver-based metabolism in humans human are needed
•  Liver humanized models in rodents based on genetic modification or “chimeric” livers show some promise in this area
•  The pros and cons of the use of each type of systems will be described and illustrated with examples
 

11:40 Distribution, Metabolism and Excretion - A case study on hepatocyte transporters at Genentech

Laurent Salphati

Laurent Salphati, Principal Scientist, Genentech, Inc.
View Bio

• In vitro and In Vivo techniques used to predict pharmacokinetic profile of a compound at a pre-clinical stage.
• Explore the use of an assay developed to measure the disposition of a compound from hepatocytes into the blood.
• Transport systems include transporters for amino acids, monocarboxylic acids, organic cations, hexoses, nucleosides, and peptides and most of these function in the direction of (mainly) efflux from liver to blood.
 

12:20 Networking Lunch

13:50 Impact of target interactions on small-molecule drug disposition: an overlooked area?

Robert van Waterschoot

Robert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
View Bio

• Relevance of target-mediated drug disposition (TMDD) for small molecules
• Impact of TMDD on pharmacokinetic parameters
• Consequences of TMDD in human microsoding studies
• When and how to evaluate TMDD for small molecules?
 

14:30 intracellular pharmacokinetics: emerging opportunities for tailoring project support

Andreas Reichel

Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
View Bio

• With significant progress in delivery technologies, peptides and peptidomimetics are receiving increasing attention as potential therapeutics for intracellular applications
• Analyses of the intracellular behaviour of peptides are a challenge making knowledge on the intracellular PK of peptides limited
• Defining structure–activity relationship of peptides with respect to intracellular residence time and proteolytic breakdown is complex
• Useful in in vitro efficacy, safety and toxicology testing and a potential link to the optimisation of in-vivo assessments and predictive pharmacology
 

15:10 Afternoon Tea

15:40 Will in silico ever replace in vitro DMPK studies

16:20 The future of pre-clinical studies - an update from Chiesi Farmaceutici

17:00 Chairman’s Closing Remarks and Close of Day Two

+

FEATURED SPEAKERS

Andreas Reichel

Andreas Reichel

VP, Head Research Pharmacokinetics, Bayer
Eric Blomme

Eric Blomme

Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
Ian Wilson

Ian Wilson

Chair, Drug Metabolism and Molecular Toxicology, Imperial College
Laurent Salphati

Laurent Salphati

Principal Scientist, Genentech, Inc.
Pau Aceves

Pau Aceves

Associate Director, Certara Strategic Counselling
Robert van Waterschoot

Robert van Waterschoot

Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
Timothy Schulz-Utermoehl

Timothy Schulz-Utermoehl

Director of DMPK, Sygnature Discovery Ltd

Andreas Reichel

VP, Head Research Pharmacokinetics, Bayer
Andreas Reichel

Andreas is Vice President and Head of Research Pharmacokinetics at Bayer Pharmaceuticals Research and Development. His department operates at two sites, Berlin and Wuppertal, and is responsible for the DMPK support of drug discovery projects of all therapeutic areas of Bayer Pharma including cardiology, oncology, and gynaecological therapy.
Andreas received his PhD in Cell Biology from the University of Leipzig in 1994 studying the regulation of nutrient transport processes at the blood-brain barrier (BBB) in vivo under the supervision of Prof. Armin Ermisch.
Between 1994 and 1997 he was working in the laboratories of Profs. Joan Abbott and David Begley, King’s College London, where he became interested in in vitro models of the BBB. Funded by several pharmaceutical companies he started working on approaches to assess and predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity. In 2000, Andreas joined Schering AG in Berlin where he helped setting up and soon became to lead the department of Research Pharmacokinetics with responsibility for in vitro ADME assays and in vivo PK studies as well as all PK and PK/PD modelling activities to predict the PK and the therapeutic dose in human. After the merger with Bayer in 2006, both RPK departments were combined under his leadership supporting all drug discovery projects of Bayer’s Pharma portfolio starting from lead discovery, through to lead optimisation and candidate selection and profiling, and beyond for both small molecules and biologics.
 

Eric Blomme

Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
Eric Blomme

Eric Blomme is Vice President, Global Preclinical Safety at Abbvie Inc. Eric has held several positions at Abbott/AbbVie, including Director Investigative Toxicology and Pathology, Director Integrated Pharmacology, and Project Leader Discovery Advanced Technologies. Prior to joining AbbVie, he worked at Pharmacia and Searle.
Eric attended the University of Lyon (Doctor in Veterinary Medicine), McGill University (Business School), Cornell University (Residency in Pathology) and The Ohio State University (PhD). Eric is Diplomate of the American College of Veterinary Pathologists. He has published over 70 peer-reviewed manuscripts, multiple editorials, several book chapters, and a book.
 

Filipe Lopes

DMPK Laboratory Head, Roche
Filipe Lopes

After completing a PhD in Analytical Chemistry at King’s College London 2012, Filipe initiated his professional career at Novartis NIBR, in the UK where he helped setting-up a new mass spectrometry based lab to support enzymology studies within respiratory diseases. Decided to expand his skill set in DMPK, and in particular Drug Metablism, gained experience as a Biotransformation and Senior DMPK Scientist at Pharmaron and Evotec and in 2015 joined Roche pRED Basel as Laboratory Head in Drug Metabolism. Currently, Filipe is involved in projects that cover a wide variety of modalities (Small and Large molecules) across various therapeutic areas, including Oncology and Neurosciences.

Ian Wilson

Chair, Drug Metabolism and Molecular Toxicology, Imperial College
Ian Wilson

Ian D Wilson worked in the pharmaceutical industry for 36 years, most recently as a senior Principal Scientist in the Dept. of Drug Metabolism and Pharmacokinetics at the AstraZeneca research site at Alderley Park in Cheshire, in the UK. In 2012 he moved to Imperial College (London) where he is Professor of Drug metabolism and Molecular Toxicology in the Dept of Surgery and cancer. His research is centred on metabolic phenotyping, drug metabolism, the microbiome and drug bioanalysis, with a particular emphasis on xenobiotic metabolism as a source of adverse drug reactions.

Kunal Taskar

Senior Investigator & Associate Fellow, GSK
Kunal Taskar

Laurent Salphati

Principal Scientist, Genentech, Inc.
Laurent Salphati

Dr. Laurent Salphati is currently Principal Scientist in the Drug Metabolism and
Pharmacokinetics department at Genentech, Inc. He heads the Drug Transporter
group and has been supporting and leading immunology and oncology project teams
from preclinical discovery to late stage clinical development. He received his Pharm.D.
from the University of Paris XI, France, and conducted his Ph.D research,
investigating the complementary roles of P-glycoprotein and CYP3A in drug
absorption and disposition, at the University of California, San Francisco under the
guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics
and pharmacodynamics of drugs, and the role of drug transporters in drug
absorption and disposition.
 

Pau Aceves

Associate Director, Certara Strategic Counselling
Pau Aceves


Pau Aceves joined Certara Strategic Consulting in February 2017. Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice—including Community, Clinical and Production Pharmacy—Pau focused his professional career path in the field of Quantitative Clinical Pharmacology (QCP) and PK/PD Modeling & Simulation, since 2006.


Pau Aceves holds a Master’s Degree in PK/PD Modeling & Simulation from the University of Manchester in the UK. His MSc project was on an Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate.


In addition to having worked on QCP-type studies (ie, food effect, bioavailability, DDIs), Pau also has a wide range of experience on other modalities, including: First-in-human (SAD/MAD), Proof-of-mechanism (PoM), Proof-of-concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) protocols; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development.


He has a total of 11 years of QCP experience in the design, analysis and reporting of studies in a wide range of therapeutic areas across all phases of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methods, eg, Population PK/PD, Physiologically-based Pharmacokinetic modeling, and Quantitative Systems Pharmacology approaches.
 

Peter Littlewood

Director DMPK, Vertex Pharmaceuticals
Peter Littlewood

Robert van Waterschoot

Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
Robert van Waterschoot

Dr. Robert A.B. van Waterschoot is currently a Group Head of DMPK/PD Project Leaders at the Roche Innovation Centers in Basel, Copenhagen and New York.

Prior to his career at Roche, he acquired experience in the DMPK departments of Merck (USA), Solvay Pharmaceuticals (the Netherlands) and Abbott/AbbVie (Germany).

Dr. Van Waterschoot has an MSc degree in Molecular Toxicology from the VU University Amsterdam and a PhD degree in Pharmacokinetics & Drug Toxicity from the Dutch Cancer Institute in Amsterdam. He has more then 20 peer-reviewed publications in the field of DMPK.
 

Timothy Schulz-Utermoehl

Director of DMPK, Sygnature Discovery Ltd
Timothy Schulz-Utermoehl

Dr Schulz-Utermoehl has over 19 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and NED of Belfry Therapeutics.

Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.
 

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.